Tech Company Financing Transactions
Aduro BioTech Funding Round
Foresite Capital, Morningside Group and OrbiMed invested in a $51.4 million funding round for Aduro BioTech. The round was announced on 12/31/2014.
Transaction Overview
Company Name
Announced On
12/31/2014
Transaction Type
Venture Equity
Amount
$51,388,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Aduro Biotech is a clinical-stage cancer immunotherapy company, the company's lead candidate -- an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Isaacs
Chief Medical Officer
Natalie Sacks
Chief Operating Officer
Gregory Schafer
Chief Operating Officer
Hans van Eenennaam
Chief Scientific Officer
Andrea van Elsas
Vice President
Anne Moon
VP - Bus. Development
Aimee Murphy
VP - Finance
Jennifer Lew
VP - General Counsel
Celeste Ferber
VP - General Counsel
Blaine Templeman
VP - Human Resources
Nancy Kaplan
VP - Operations
Quoc Le-Nguyen
VP - Operations
Aimee Murphy
VP - Operations
Justin Skoble
VP - R & D
Dirk Brockstedt
VP - Regulatory Affairs
Michele DeVries
VP - Regulatory Affairs
Sylvia Wheeler
Browse more venture capital transactions:
Prev: 12/31/2014: Just Push Pay venture capital transaction
Next: 12/31/2014: Solstice Biologics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs